CD8A and neoplasm: Mutant RAS is capable of regulating expression of cytokines such as IL-6 and IL-8 in a variety of in vitro and in vivo models leading to tumor progression and infiltration of multiple immune cell types such as myeloid cells, CD8+ T cells, Tregs, IL-17-producing lymphocytes (as reviewed elsewhere [66,67,68]).